Bourn W M, Garrett R L, Reigel C E, Risinger F O
Psychopharmacology (Berl). 1985;85(3):267-70. doi: 10.1007/BF00428185.
The influence of the benzodiazepine (BZ) receptor antagonist Ro 15-1788 on the convulsant properties of flurazepam (FLZ) was studied in rats. Animals were prepared with chronic epidural electrodes for EEG recording and respiratory rates were recorded via a rubber bulb connected to a pressure transducer. FLZ convulsive thresholds were determined by continuous IV infusion in the presence and absence of Ro 15-1788 pretreatment. All animals receiving the FLZ infusion experienced convulsions preceded by dose-dependent reduction of respiratory rate. Pretreatment with Ro 15-1788 substantially reduced the FLZ convulsive threshold, suggesting a blockade of the depressant (anticonvulsant) aspect of the FLZ effect, thus, augmenting a convulsant effect at a separate receptor. An alternate hypothesis is that Ro 15-1788 may increase the affinity or intrinsic activity of the receptor responsible for the convulsant aspect of FLZ. Ro 15-1788 did not appear to alter the respiratory rate depressant effect of FLZ, although early onset of convulsions in the pretreated animals precluded measurement of respiration at the higher dose of FLZ allowable in animals that were not pretreated with the antagonist.
在大鼠中研究了苯二氮䓬(BZ)受体拮抗剂Ro 15 - 1788对氟西泮(FLZ)惊厥特性的影响。动物通过慢性硬膜外电极进行脑电图记录,并通过连接压力传感器的橡胶球记录呼吸频率。在有和没有Ro 15 - 1788预处理的情况下,通过连续静脉输注测定FLZ惊厥阈值。所有接受FLZ输注的动物在惊厥前均出现呼吸频率呈剂量依赖性降低。Ro 15 - 1788预处理显著降低了FLZ惊厥阈值,表明FLZ作用的抑制(抗惊厥)方面被阻断,从而在另一个受体上增强了惊厥作用。另一种假设是,Ro 15 - 1788可能会增加负责FLZ惊厥方面的受体的亲和力或内在活性。Ro 15 - 1788似乎并未改变FLZ对呼吸频率的抑制作用,尽管预处理动物中惊厥的早期发作排除了在未用拮抗剂预处理的动物中允许的较高剂量FLZ下对呼吸的测量。